Gilead Sciences, Inc. (GILD) Shares Sold by Pendal Group Ltd

Pendal Group Ltd lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 14.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 151,010 shares of the biopharmaceutical company’s stock after selling 24,686 shares during the period. Pendal Group Ltd’s holdings in Gilead Sciences were worth $11,659,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp raised its position in Gilead Sciences by 11.6% during the second quarter. Bank of New York Mellon Corp now owns 30,936,970 shares of the biopharmaceutical company’s stock worth $2,191,575,000 after acquiring an additional 3,221,439 shares during the last quarter. Swedbank raised its position in Gilead Sciences by 103.7% during the third quarter. Swedbank now owns 3,906,172 shares of the biopharmaceutical company’s stock worth $301,596,000 after acquiring an additional 1,988,987 shares during the last quarter. Natixis raised its position in Gilead Sciences by 4,550.6% during the second quarter. Natixis now owns 1,913,535 shares of the biopharmaceutical company’s stock worth $135,555,000 after acquiring an additional 1,872,389 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. raised its position in Gilead Sciences by 1,631.7% during the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 997,656 shares of the biopharmaceutical company’s stock worth $70,674,000 after acquiring an additional 940,044 shares during the last quarter. Finally, Sanders Capital LLC raised its position in Gilead Sciences by 7.0% during the second quarter. Sanders Capital LLC now owns 10,579,575 shares of the biopharmaceutical company’s stock worth $804,126,000 after acquiring an additional 696,200 shares during the last quarter. 78.09% of the stock is currently owned by hedge funds and other institutional investors.

In related news, Director John C. Martin sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $74.16, for a total transaction of $3,708,000.00. Following the completion of the transaction, the director now owns 3,067,762 shares of the company’s stock, valued at $227,505,229.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 150,000 shares of company stock valued at $11,087,500 in the last ninety days. 1.30% of the stock is currently owned by company insiders.

NASDAQ:GILD opened at $71.88 on Friday. The company has a quick ratio of 3.39, a current ratio of 3.47 and a debt-to-equity ratio of 1.36. The company has a market capitalization of $91.20 billion, a PE ratio of 8.40, a PEG ratio of -2.73 and a beta of 1.01. Gilead Sciences, Inc. has a 1-year low of $64.27 and a 1-year high of $89.54.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. Gilead Sciences had a net margin of 7.12% and a return on equity of 39.32%. The business had revenue of $5.60 billion during the quarter, compared to analyst estimates of $5.44 billion. During the same quarter in the previous year, the business posted $2.27 earnings per share. Research analysts anticipate that Gilead Sciences, Inc. will post 6.44 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 28th. Investors of record on Friday, December 14th will be given a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a yield of 3.17%. The ex-dividend date is Thursday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is 26.64%.

A number of equities analysts have issued reports on GILD shares. Piper Jaffray Companies set a $85.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, September 12th. Mizuho restated a “buy” rating and set a $94.00 target price on shares of Gilead Sciences in a research report on Friday, August 10th. Zacks Investment Research upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $86.00 target price for the company in a research report on Wednesday, July 18th. BidaskClub upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, October 11th. Finally, Evercore ISI restated a “buy” rating on shares of Gilead Sciences in a research report on Wednesday, October 31st. Twelve research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Gilead Sciences presently has a consensus rating of “Buy” and a consensus price target of $87.84.

COPYRIGHT VIOLATION WARNING: “Gilead Sciences, Inc. (GILD) Shares Sold by Pendal Group Ltd” was first published by WKRB News and is the property of of WKRB News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://www.wkrb13.com/2018/11/10/gilead-sciences-inc-gild-shares-sold-by-pendal-group-ltd.html.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

See Also: Price to Earnings Ratio (PE) Basics

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply